|
|
Profile
|
Delegates :
Kiyoshi Eshima, PhD, |
|
Incorporated :
December 6 , 2010 |
Paid in Capital :
2795 Million yen |
Employees :
人 |
Address :
37-5 Nishikino, Miyajima, Kawauchi-cho TOKUSHIMA
〒771-0116
|
TEL/FAX :
+81-3-6231-1278 / +81-3-6231-1478 |
URL：
https://www.delta-flypharma.co.jp/index.html |
Attachment :
|
Mission/Background :
Delta-Fly is a drug discovery startup that specializes in anticancer agents using module technology(discussed later). It aims to develop anticancer treatments gentle on the body and the wallet. Current president Kiyoshi Eshima established the company in December 2010 in Tokushima, gathering a team of colleagues with over 20 years' experience in anticancer agent development. The company listed on TSE Mothers in October 2018. |
|
Technology & Business
|
Using its proprietary module technology, pharmaceutical company Delta-Fly conducts R&D into new anticancer agents. Module technology is a unique drug discovery method that takes the active ingredients (modules) of anticancer agents from existing drugs whose patents have expired or whose development was halted due to side effects and combines them to create new drugs with an improved balance of clinical efficacy and safety. Anticancer agents usually take over 10 years to develop. However, very little basic research is necessary in module technology, which lowers development risks and enables potential approval after R&D of six to eight years. The new agents are patentable as new drugs.
|
|
Products & Service
|
Products & Service Name
|
Stage
|
Outline
|
Milestone
|
DFP-10917 (Cell cycle regulator)
|
Phase3
|
Relapsed/refractory acute myeloid leukemia (AML)
|
Launch date scheduled for 2022
|
DFP-14323 (Cancer immuno modulator)
|
Phase2
|
Non-small cell lung cancer (NSCLC)
|
Launch date scheduled for 2023
|
DFP-11207 (Cancer cell metabolism regulator)
|
Phase1
|
Solid tumor (Pancreatic cancer, other)
|
Launch date scheduled for 2024
|
DFP-14927 (Polymeric agent of anti-tumor drug)
|
Phase1
|
Solid tumor, Hematopoietic tumor
|
Launch date scheduled for 2025
|
DFP-10825 (Oligonucleotide therapeutics)
|
Preclinical
|
Peritoneal disseminated metastatic cancer
|
Launch date scheduled for 2026
|
|
Highlights
|
DFP-10917: Delta-Fly resubmitted the protocol to the FDA, and began preparations to enroll patients for the Phase 3 study.
DFP-14323: To speed up the Phase 2 study that is currently underway by expanding the number of facilities.
DFP-11207: Phase 1 study and the food effect study was completed, thereafter was presented at ASCO.
DFP-14927: The FDA completed a safety review, and obtained IND approval.
DFP-10825: It started preparing to manufacture new API and formulations with Phase 1 study.
|
|
Alliance strategy
|
The company would like to collaborate with pharmaceutical company in Europe and US in markets.
|
|
|